Y-mabs resubmits cancer drug for marketing approval in the US

After several years’ delay, Y-mabs has now filed another marketing application for cancer drug candidate with the US health authority after the first was rejected in 2020.

Photo: Kelly Davidson Photography

Danish-American biotech firm Y-mabs has announced it has resubmitted a Biologics License Application (BLA) for its delayed cancer drug candidate, omburtamab, with the US health authority, according to a company press release on Thursday last week.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs